|
?:authorAffiliation
|
-
[\'Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.\', \'Department of Chemistry, Purdue University, West Lafayette, Indiana, USA.\', \'Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana, USA.\', \'Experimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.\', \'Viral Oncology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.\', \'Kumamoto Innovative Development Organization, Kumamoto University, Kumamoto, Japan.\', \'Department of Environmental and Molecular Health Sciences, Faculty of Medical and Pharmaceutical Science, Kumamoto University, Kumamoto, Japan.\', \'Department of Laboratory Animal Medicine, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.\', \'Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan hiroaki.mitsuya2@nih.gov hmitsuya@hosp.ncgm.go.jp.\', \'Department of Clinical Sciences, Kumamoto University Hospital, Kumamoto, Japan.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}